The Co-Chief Investment Strategist at John Hancock Investment Management, Emily Roland, believes that we’re in a period of serious disinflation. Roland joined CNBC’s ‘Squawk Box’ on June 18 to discuss the latest market trends and emphasize the critical role of housing data in the Fed’s decisions, rather than a singular focus on the political backdrop and potential inflationary impact of tariffs. She believes that this housing disinflation will eventually feed into broader economic data. She warns that the Fed is currently in a wait-and-see mode due to tariffs and is potentially reluctant to cut rates. This action, or rather inaction, could lead to more rate cuts than investors currently anticipate by the end of 2025.
Roland also acknowledged the possibility that these disinflationary factors could completely offset the inflationary impact of tariffs. She highlighted that the US economy is primarily service-based, not goods-based, which suggests that service-sector disinflation could be strong enough to overcome potential tariff-driven inflation. Roland also clarified that while she does not foresee a recession, she anticipates a slowly decelerating growth trend.
That being said, we’re here with a list of the 11 best most active stocks to buy according to analysts.
A portfolio manager in front of their computer screen, evaluating a variety of mid-cap stocks.
Methodology
We first used stock screeners to compile a list of active stocks with high average 3-month volumes. We then selected 11 stocks that had a high average upside potential of over 25%. The stocks are ranked in ascending order of their average upside potential. We’ve also added the hedge fund sentiment for each stock, which was sourced from Insider Monkey’s database, as of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Most Active Stocks To Buy According to Analysts
11. Schlumberger Limited (NYSE:SLB)
Number of Hedge Fund Holders: 68
Average Volume (3-Month): 17 million
Average Upside Potential as of June 20: 28.35%
Schlumberger Limited (NYSE:SLB) is one of the most active stocks to buy according to analysts. Earlier last month, in May, Schlumberger introduced Electris, which is a new portfolio of digitally enabled electric well completions technologies. These technologies are designed to enhance oil & gas production and recovery while simultaneously reducing the total cost of ownership for an asset.
The announcement was made at the Offshore Technology Conference in Houston, Texas. Electris completions digitalize control of the entire productive area of the wellbore and provide real-time production intelligence across the reservoir. The real-time data allows operators to anticipate, adjust, and react confidently to dynamic production conditions. It also enables access to reserves that conventional systems typically leave behind.
The Electris technology has already seen over 100 installations across 5 countries. As an example, in Norway, Electris completions were deployed offshore in an extended-reach well to boost oil production. The system’s intelligence helps the operator identify which zones are contributing to production, which optimizes oil output and minimizes produced water. By controlling water production, Electris completions have reduced the energy required to lift and reinject treated water back into the reservoir.
Schlumberger Limited (NYSE:SLB) provides technology for the energy industry worldwide. It has 4 divisions: Digital & Integration, Reservoir Performance, Well Construction, and Production Systems.
10. DuPont de Nemours Inc. (NYSE:DD)
Number of Hedge Fund Holders: 64
Average Volume (3-Month): 3.37 million
Average Upside Potential as of June 20: 28.44%
DuPont de Nemours Inc. (NYSE:DD) is one of the most active stocks to buy according to analysts. At the start of June, DuPont showcased its cutting-edge interconnect innovations for AI and next-gen electronics at the Total Solution Exhibition for Electronic Equipment 2025 (JPCA Show 2025). The event took place from June 4-6 at the Tokyo Big Sight East Exhibition Halls in Tokyo, Japan.
DuPont’s participation highlighted its commitment to innovation within the electronics industry, building on 50+ years of collaboration with industry leaders. The company’s focus is on integrated circuit (IC) substrates, advanced printed circuit boards (PCBs), and advanced packaging, all of which are critical for empowering advanced computing and connectivity, especially with the surge in demand for high-performance IC substrates driven by the expanding AI ecosystem.
Japan is a leader in innovative materials and processes for advanced substrates vital for bridging AI chips and PCBs. DuPont’s offerings for IC substrate manufacturers aim to accelerate product development and boost production efficiency. Key solutions include DuPont Circuposit desmear & electroless copper for mSAP & SAP processes, and DuPont Copper Gleam electrolytic copper for conformal through-hole plating, which enhances core layer plating technologies.
DuPont de Nemours Inc. (NYSE:DD) provides technology-based materials and solutions through Electronics & Industrial, Water & Protection, and Corporate & Other segments.
9. Alaska Air Group Inc. (NYSE:ALK)
Number of Hedge Fund Holders: 56
Average Volume (3-Month): 3.33 million
Average Upside Potential as of June 20: 29.84%
Alaska Air Group Inc. (NYSE:ALK) is one of the most active stocks to buy according to analysts. Earlier in May, Alaska Airlines inaugurated a new daily nonstop service between Seattle and Tokyo Narita. This marked a new phase of widebody international flying for Alaska Airlines, with flights operated by Hawaiian Airlines’ long-haul aircraft.
The new connection aims to transform Seattle-Tacoma International Airport/SEA, already the West Coast’s largest airline hub serving 104 nonstop North American destinations, into a premier global gateway. Seattle is geographically closer to Tokyo, being 7% closer than San Francisco and 13% closer than Los Angeles.
The airline plans to serve at least 12 international destinations with widebody aircraft from Seattle by 2030, including destinations in Europe. Tokyo Narita and Seoul Incheon are the first two long-haul additions in this expansion plan. There has been significant interest in the Tokyo flights, with half of the US tickets sold for Narita originating from over 80 cities outside Seattle. Nonstop flights between Seattle and Seoul are set to commence on September 12.
Alaska Air Group Inc. (NYSE:ALK) operates airlines through three segments: Alaska Airlines, Hawaiian Airlines, and Regional.
8. DraftKings Inc. (NASDAQ:DKNG)
Number of Hedge Fund Holders: 70
Average Volume (3-Month): 10.83 million
Average Upside Potential as of June 20: 30.83%
DraftKings Inc. (NASDAQ:DKNG) is one of the most active stocks to buy according to analysts. Earlier on June 12, DraftKings announced that it will introduce a 50-cent transaction fee on all mobile and online bets placed through DraftKings Sportsbook in Illinois. This new fee will take effect on September 1 this year.
The decision comes in direct response to recent and prior increases in sports wagering taxes passed by the Illinois state legislature, which apply to all mobile and online sports wagers placed with licensed operators. This move by DraftKings follows a similar announcement by FanDuel earlier this month, which plans to implement an identical 50-cent charge starting July 1, after the introduction of the Illinois Transaction Fee under House Bill 1928.
The new per-bet tax, effective July 1, will impose a 25-cent fee per wager for the first 20 million wagers taken by licensed sportsbooks, increasing to 50 cents per wager thereafter. This is expected to generate ~ $36 million in additional revenue for the state. DraftKings maintains that it supports collaborative policymaking that ensures the long-term sustainability of the industry and contributes to state revenue.
DraftKings Inc. (NASDAQ:DKNG) is an international digital sports entertainment and gaming company. It provides online sports betting, daily fantasy sports, media, digital lottery courier, media, and other products, as well as retail sportsbooks.
7. SharkNinja Inc. (NYSE:SN)
Number of Hedge Fund Holders: 69
Average Volume (3-Month): 2.05 million
Average Upside Potential as of June 20: 32.16%
SharkNinja Inc. (NYSE:SN) is one of the most active stocks to buy according to analysts. On June 9, SharkNinja announced a partnership with Apple Original Films for their upcoming movie, F1 The Movie. This highly anticipated film is set to hit theaters and IMAX this summer, distributed by Warner Bros. Pictures. As an official sponsor of the film’s APXGP racing team, SharkNinja is bringing its commitment to high performance and precision to the thrilling world of cinematic racing.
SharkNinja has launched a limited-edition APXGP Performance Collection, inspired by F1 The Movie. This official film collection is now available and features 7 popular products, reimagined with a sleek black and gold design. It includes the Ninja CREAMi Ice Cream Maker, the Ninja FrostVault Wheeled Cooler with Dry Zone, the Shark PowerDetect 2-in-1 Robot Vacuum and Mop with NeverTouch Pro Base, the Shark FlexBreeze Pro Mist fan, the Shark PowerDetect Clean & Empty System cordless vacuum, the Shark SpeedStyle Pro hair styler, and the Shark FlexStyle Air Styling & Drying System.
Moviegoers will be able to see SharkNinja’s sponsorship of the APXGP race team prominently featured in F1 The Movie. The launch of this limited-edition product line is also being supported by custom co-branded television spots, and attentive viewers may even spot some favorite SharkNinja products within the film. The SharkNinja limited-edition APXGP Performance Collection is currently available for a limited time on SharkClean.com, NinjaKitchen.com, and SharkBeauty.com.
SharkNinja Inc. (NYSE:SN) is a product design and technology company that provides various solutions for consumers internationally.
6. AstraZeneca (NASDAQ:AZN)
Number of Hedge Fund Holders: 56
Average Volume (3-Month): 5.41 million
Average Upside Potential as of June 20: 34.38%
AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results for AstraZeneca’s surovatamig, a next-gen CD19xCD3 bispecific T-cell engager (BiTE), were presented at the 2025 Congress of the European Hematology Association (EHA 2025). The event was held from June 12 to 15 in Milan, Italy.
The findings come from the global, multicenter, open-label, and single-arm Phase I/II SYRUS clinical trial (NCT06137118), which is evaluating surovatamig as a monotherapy for patients aged 12 and over with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). B-ALL is an aggressive hematologic malignancy that accounts for 7% to 85% of all acute lymphoblastic leukemia cases and is most commonly diagnosed in young children and adolescents, although its incidence also rises in older adults.
Surovatamig is designed with Fc-engineering for an extended half-life and optimized CD3 binding, which allows for intermittent dosing and controlled T-cell activation. This could offer a convenient and safer alternative to continuous infusion therapies like Blincyto. Beyond R/R B-ALL, surovatamig is also in Phase III trials as a monotherapy for diffuse large B-cell lymphoma and in combination with Biogen’s Rituxan (rituximab) for untreated follicular lymphoma. While surovatamig shows promise, it will need to demonstrate superior performance against established therapies such as Blincyto and Aucatzyl.
AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines.
5. Novo Nordisk (NYSE:NVO)
Number of Hedge Fund Holders: 60
Average Volume (3-Month): 000
Average Upside Potential as of June 20: 34.75%
Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another for a once-daily oral formulation. These were published in The Lancet.
Both formulations will progress to Phase 3 for weight management, which is a move supported by completed clinical studies and positive feedback from regulatory authorities. The executive vice president for Development at Novo Nordisk, Martin Holst Lange, expressed satisfaction with the results and regulatory feedback and highlighted the company’s commitment to addressing obesity and expanding treatment options.
Amycretin is a unimolecular, long-acting GLP-1 and amylin receptor agonist, which is designed to target appetite regulation. It is being developed for adults with overweight or obesity, and also as a potential treatment for adults with type 2 diabetes. While Amycretin is not yet approved in the US for weight loss, these positive early-phase results strongly support its continued investigation in larger and longer-term Phase 3 trials to further assess its efficacy and safety.
Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease.
4. Fiserv Inc. (NYSE:FI)
Number of Hedge Fund Holders: 72
Average Volume (3-Month): 5.06 million
Average Upside Potential as of June 20: 37.72%
Fiserv Inc. (NYSE:FI) is one of the most active stocks to buy according to analysts. On June 17, Fiserv announced a new collaboration with Early Warning Services to offer Paze, which is a digital wallet solution. The partnership aims to provide financial institutions and merchants with a convenient and secure digital checkout experience for consumers.
Paze allows banks and credit unions to offer a digital wallet where eligible credit and debit cards are consolidated. A key security feature of Paze is tokenization, which replaces actual card account numbers with unique tokens and prevents card numbers from being shared directly with merchants. Paze has already integrated over 150 million credit and debit cards.
Fiserv will also enable merchants to accept Paze across its e-commerce payments suite. The collaboration deepens a long-standing alliance between Fiserv and Early Warning Services, which previously saw Fiserv offering a turnkey service for Zelle for P2P payments.
Fiserv Inc. (NYSE:FI) provides payments and financial services technology solutions through the Merchant Solutions and Financial Solutions segments.
3. Thermo Fisher Scientific Inc. (NYSE:TMO)
Number of Hedge Fund Holders: 101
Average Volume (3-Month): 2.71 million
Average Upside Potential as of June 20: 40.75%
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept.
The partnership will use Ethris’ advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific’s industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities.
Ethris’ platform technologies have already shown promising results. Specifically, the company’s lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability.
The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines.
Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins.
2. JD.com Inc. (NASDAQ:JD)
Number of Hedge Fund Holders: 66
Average Volume (3-Month): 13.3 million
Average Upside Potential as of June 20: 59.43%
JD.com Inc. (NASDAQ:JD) is one of the most active stocks to buy according to analysts. On June 18, Bloomberg reported that JD.com founder Richard Liu unveiled a bold turnaround plan for the online retailer, which he described as having experienced its darkest period in the past half-decade. During a rare news conference at JD’s Beijing headquarters on June 17, Liu, aged 52, admitted that the company lost its way since a 2020 government crackdown, allowing rivals like PDD Holdings Inc. (NASDAQ:PDD) to surge ahead.
He characterized the past 5 years as lost and lacking innovation and progress, deeming them the most unremarkable and least valuable five years in his entrepreneurial history. Liu’s turnaround strategy focuses on using JD’s extensive logistics network to expand into new markets, including food delivery and travel. In March, JD made an aggressive entry into China’s over $80 billion food delivery market, a domain previously dominated by Meituan (OTC:MPNGF) and Alibaba Group Holding Limited’s (NYSE:BABA) Ele.me.
Beyond food delivery, JD also plans to challenge Meituan in the hotel and flight booking market by offering a 3 year membership program that waives commissions for hotels. Globally, JD aims to launch its e-commerce platform in Europe in 2026, having already spent 3 years building the necessary infrastructure there.
JD.com Inc. (NASDAQ:JD) operates as a supply chain-based technology and service provider in the People’s Republic of China. It has three segments: JD Retail, JD Logistics, and New Businesses.
1. Cytokinetics Incorporated (NASDAQ:CYTK)
Number of Hedge Fund Holders: 64
Average Volume (3-Month): 2.09 million
Average Upside Potential as of June 20: 118.93%
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts. Earlier in May, Cytokinetics announced the presentation of additional data regarding aficamten at the European Society of Cardiology Heart Failure 2025 Congress. The new findings stem from two analyses of SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy/HCM. Additionally, results from a real-world analysis concerning non-obstructive HCM were also presented.
The efficacy data of aficamten in obstructive HCM patients with mild symptoms from SEQUOIA-HCM were simultaneously published in The European Heart Journal. The Vice President and Head of Clinical Research at Cytokinetics, Stephen Heitner, M.D., stated that these analyses from SEQUOIA-HCM show that aficamten’s effects on exercise capacity, symptoms, hemodynamics, and cardiac biomarkers are consistent across patients with obstructive HCM, regardless of their baseline symptom severity or geographic region.
Aficamten is an investigational selective and small-molecule cardiac myosin inhibitor designed to reduce myocardial hypercontractility in HCM by preventing myosin from entering a force-producing state. It has received Breakthrough Therapy Designation from the US FDA for symptomatic HCM and from China’s NMPA for symptomatic obstructive HCM.
The drug is currently under regulatory review in the US, with a Prescription Drug User Fee Act/PDUFA target action date of December 26 this year. It is also under review by the European Medicines Agency/EMA and the Center for Drug Evaluation/CDE of China’s National Medical Products Administration/NMPA with Priority Review.
Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating diseases in the US.
While we acknowledge the potential of CYTK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CYTK and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None.
